Compare PMVP & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMVP | MCHX |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.5M | 66.3M |
| IPO Year | 2020 | 2003 |
| Metric | PMVP | MCHX |
|---|---|---|
| Price | $1.36 | $1.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 455.5K | 11.7K |
| Earning Date | 03-06-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $90,291,000.00 |
| Revenue This Year | N/A | $9.12 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.82 | $1.26 |
| 52 Week High | $1.88 | $2.30 |
| Indicator | PMVP | MCHX |
|---|---|---|
| Relative Strength Index (RSI) | 48.20 | 58.00 |
| Support Level | $1.26 | $1.35 |
| Resistance Level | $1.39 | $1.60 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 38.46 | 89.78 |
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.